Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dyadic International, Inc. - Common Stock (NQ:DYAI)

1.140 -0.040 (-3.39%)
Streaming Delayed Price Updated: 3:57 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dyadic International, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company
From Dyadic International, Inc.
Via GlobeNewswire
Top 5 Active Stock Buzzers Under $10: INBS, PLUG, KOPN, DYAI, MINM
Via AB Newswire
Dyadic to Attend BIO CEO & Investor Conference and European Industry Events
From Dyadic International, Inc.
Via GlobeNewswire
Latest Buzz on The Street: Noteworthy Developments at DYAI, ELEV, ATRA, ESPR, KAVL
Via AB Newswire
Recap: Dyadic International Q3 Earnings
 
Via Benzinga
“Revolutionizing Biotechnology: Dyadic International (NASDAQ: DYAI) Leads with C1 Platform for Swift and Efficient Protein Production”
Via AB Newswire
Bull Run 2024: Biopharma Healthcare Stocks Surge, Gaining Momentum: DYAI, ABVC, FWBI, VTAK, NEXI
Via AB Newswire
“Dyadic International Inc. (NASDAQ: DYAI): Zacks Small-Cap Research Indicates Valuation at $9.00 per Share”
Via AB Newswire
“Dyadic International (NASDAQ: DYAI) Revolutionizing Pharma with Innovative C1 Technology for Global Protein Development”
Via AB Newswire
Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference
From Dyadic International, Inc.
Via GlobeNewswire
“2024 Market Outlook: SmallCap Radar Stocks Unveiled”: DYAI, SKYX, QUBT, KNW, VTAK
Via AB Newswire
Topics Intellectual Property
“Dyadic International Inc. (NASDAQ: DYAI) Advances Biopharmaceutical Innovations and Vaccine Manufacturing Globally”
Via AB Newswire
CryptoNewsBreaks – Innovators and Ideas Showcased at 12th Annual Benchmark Discovery Conference
Via Investor Brand Network
InvestorNewsBreaks – Standouts from 12th Annual Benchmark Discovery Conference Featured in Nasdaq Article
Via Investor Brand Network
Dyadic Attends Investor Events in December
From Dyadic International, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
From Dyadic International, Inc.
Via GlobeNewswire
Dyadic’s C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa
From Dyadic International, Inc.
Via GlobeNewswire
Dyadic to Present at Industry Events in November
From Dyadic International, Inc.
Via GlobeNewswire
Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
From Dyadic International, Inc.
Via GlobeNewswire
Dyadic Appoints Doug Pace to Its Executive Leadership Team
From Dyadic International, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic
From Dyadic International, Inc.
Via GlobeNewswire
Dyadic to Present at Industry and Investor Events in October
From Dyadic International, Inc.
Via GlobeNewswire
Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells
From Dyadic International, Inc.
Via GlobeNewswire
Dyadic Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus™
From Dyadic International, Inc.
Via GlobeNewswire
Dyadic to Present at BioProcess International
From Dyadic International, Inc.
Via GlobeNewswire
Dyadic Announces Continued Progress Towards Commercialization of Animal-Free Recombinant Serum Albumin
From Dyadic International, Inc.
Via GlobeNewswire
Dyadic to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
From Dyadic International, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.